Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Open-label, Multi-centre, Platform Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Multiple Anti-Cancer Agents in Metastatic Prostate Cancer

NCT07590934 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07590934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07590934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Open-label, Multi-centre, Platform Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Multiple Anti-Cancer Agents in Metastatic Prostate Cancer
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 3, 2026
Completion date
September 25, 2029
Enrollment
152 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer